Christine Y. Lu, PhD

This analysis demonstrated significant variability in medical policy determinations and evidence cited for clinically relevant pharmacogenetic tests among major US health insurers and laboratory benefit managers.

High-deductible health plan members with bipolar disorder experienced a reduction in nonpsychiatrist mental health provider visits but no changes in other utilization.

Rates of hepatitis C virus (HCV) treatment in a commercially insured population doubled after availability of new direct-acting antivirals. Member out-of-pocket spending was kept low while the health plan bore 99% of spending on HCV medications.